secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001628280-25-052077
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen reports Q2 FY2026 net loss $19.4M; PALISADE-3 Phase 3 complete, topline due Q4 2025
--------------------------------------------------------------------------------

- Net loss $19.4M vs $13.0M YoY; R&D expense $15.9M (up 56% YoY) on PALISADE program.
- PALISADE-3 Phase 3 trial of fasedienol for social anxiety disorder completed; topline data expected by Q4 2025.
- PALISADE-4 Phase 3 trial topline expected H1 2026; same public speaking challenge design.
- Cash, equivalents, and marketable securities $77.2M as of Sep 30, 2025.
- Paul Edick appointed to board of directors, effective October 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025052077/0001628280-25-052077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828025052077/vtgn-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-052077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer